PROPEL® SINUS

PROPEL represents a medical breakthrough clinically proven to improve the results of sinus surgery.¹

PROPEL is the first and only device clinically shown to keep the sinuses open after surgery, precisely deliver anti-inflammatory medication directly to the sinuses, and then dissolve.

The innovative sinus stent decreases post-operative scarring and inflammation, reducing the need for additional surgical procedures as well as  oral steroids¹ and their potential side effects.

1. Han JK, Marple BF, Smith TL et al. IFAR.2012; 2:271-279.

The PROPEL sinus implants are intended for use following sinus surgery to maintain the sinus openings and to locally deliver a drug to the sinuses: PROPEL for use in the ethmoid sinus, PROPEL Mini for use in the ethmoid sinus and frontal sinus opening and PROPEL Contour for use in the frontal and maxillary sinus openings. The products are intended for use in patients ≥18 years of age. These products are not intended for people who are allergic to the drug (mometasone furoate) or to certain polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, movement of the implant (within or out of the sinus), possible side effects of the drug, infection, and nose bleed. For more information on the risks and benefits of PROPEL sinus implants, please talk to your doctor. The FDA approved labeling can be found at www.IntersectENT.com. Rx only. 

INTERSECT ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries.